Denise C Hsu1, Yi Fei Ma, Sophia Hur, Danny Li, Adam Rupert, Rebecca Scherzer, S C Kalapus, Steven Deeks, Irini Sereti, Priscilla Y Hsue. 1. aNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland bUniversity of California San Francisco (UCSF), San Francisco, California cLeidos Biomedical Research, Inc, Frederick, Maryland dUniversity of California and Veterans Affairs Medical Center, San Francisco, California, USA. *These two authors contributed equally to this work.
Abstract
OBJECTIVE: To determine the associations of markers of immune activation with atherosclerosis and mortality, in participants with treated and suppressed HIV infection. DESIGN: Observational study of 149 HIV-infected participants with virologic suppression on antiretroviral therapy. METHODS: Cryopreserved mononuclear cells and plasma were used to evaluate markers of T cell and monocyte activation, inflammation and coagulopathy. Carotid artery intima-media thickness (CIMT) was measured by high-resolution ultrasound at the common, bifurcation and internal carotid regions. Associations of immunologic markers with CIMT and all-cause mortality were assessed using multivariable linear regression and Cox proportional hazards regression. RESULTS: The majority of participants were men (93%) and white (67%), median age of 48.5 years and median CD4 T-cell count of 522 cells/μl. The median baseline IMT was 1.0 mm. Over a median of 8.3-year follow-up, 12 deaths occurred. In multivariate analysis, adjusted for traditional cardiovascular risk factors, higher monocyte C-C motif chemokine receptor 5 (CCR5) expression [5.4%, P = 0.001] was associated with greater common CIMT. Higher plasma IL-6 was associated with greater bifurcation [8.0%, P = 0.007] and overall mean IMT [5.2%, P = 0.026]. Finally, higher plasma IL-6 [hazard ratio 1.9, P = 0.030], internal carotid [hazard ratio 4.1, P = 0.022] and mean IMT [hazard ratio 5.2, P = 0.026] were individually associated with all-cause mortality. CONCLUSION: Higher monocyte CCR5 expression and plasma IL-6 were associated with atherosclerosis, independent of traditional cardiovascular risk factors. IL-6 and CIMT were individually associated with all-cause mortality. The impact of therapies targeting immune activation in cardiovascular disease in treated HIV infection merits additional investigation.
OBJECTIVE: To determine the associations of markers of immune activation with atherosclerosis and mortality, in participants with treated and suppressed HIV infection. DESIGN: Observational study of 149 HIV-infectedparticipants with virologic suppression on antiretroviral therapy. METHODS: Cryopreserved mononuclear cells and plasma were used to evaluate markers of T cell and monocyte activation, inflammation and coagulopathy. Carotid artery intima-media thickness (CIMT) was measured by high-resolution ultrasound at the common, bifurcation and internal carotid regions. Associations of immunologic markers with CIMT and all-cause mortality were assessed using multivariable linear regression and Cox proportional hazards regression. RESULTS: The majority of participants were men (93%) and white (67%), median age of 48.5 years and median CD4 T-cell count of 522 cells/μl. The median baseline IMT was 1.0 mm. Over a median of 8.3-year follow-up, 12 deaths occurred. In multivariate analysis, adjusted for traditional cardiovascular risk factors, higher monocyte C-C motif chemokine receptor 5 (CCR5) expression [5.4%, P = 0.001] was associated with greater common CIMT. Higher plasma IL-6 was associated with greater bifurcation [8.0%, P = 0.007] and overall mean IMT [5.2%, P = 0.026]. Finally, higher plasma IL-6 [hazard ratio 1.9, P = 0.030], internal carotid [hazard ratio 4.1, P = 0.022] and mean IMT [hazard ratio 5.2, P = 0.026] were individually associated with all-cause mortality. CONCLUSION: Higher monocyte CCR5 expression and plasma IL-6 were associated with atherosclerosis, independent of traditional cardiovascular risk factors. IL-6 and CIMT were individually associated with all-cause mortality. The impact of therapies targeting immune activation in cardiovascular disease in treated HIV infection merits additional investigation.
Authors: Matthias W Lorenz; Joseph F Polak; Maryam Kavousi; Ellisiv B Mathiesen; Henry Völzke; Tomi-Pekka Tuomainen; Dirk Sander; Matthieu Plichart; Alberico L Catapano; Christine M Robertson; Stefan Kiechl; Tatjana Rundek; Moïse Desvarieux; Lars Lind; Caroline Schmid; Pronabesh DasMahapatra; Lu Gao; Kathrin Ziegelbauer; Michiel L Bots; Simon G Thompson Journal: Lancet Date: 2012-04-27 Impact factor: 79.321
Authors: Jason D Barbour; Emilie C Jalbert; Dominic C Chow; Louie Mar A Gangcuangco; Philip J Norris; Sheila M Keating; John Heitman; Lorna Nagamine; Todd Seto; Lishomwa C Ndhlovu; Beau K Nakamoto; Howard N Hodis; Nisha I Parikh; Cecilia M Shikuma Journal: Atherosclerosis Date: 2013-10-31 Impact factor: 5.162
Authors: Colette J Smith; Lene Ryom; Rainer Weber; Philippe Morlat; Christian Pradier; Peter Reiss; Justyna D Kowalska; Stephane de Wit; Matthew Law; Wafaa el Sadr; Ole Kirk; Nina Friis-Moller; Antonella d'Arminio Monforte; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren Journal: Lancet Date: 2014-07-19 Impact factor: 79.321
Authors: T R Glass; C Ungsedhapand; M Wolbers; R Weber; P L Vernazza; M Rickenbach; H Furrer; E Bernasconi; M Cavassini; B Hirschel; M Battegay; H C Bucher Journal: HIV Med Date: 2006-09 Impact factor: 3.180
Authors: Carl Grunfeld; Joseph A C Delaney; Christine Wanke; Judith S Currier; Rebecca Scherzer; Mary L Biggs; Phyllis C Tien; Michael G Shlipak; Stephen Sidney; Joseph F Polak; Daniel O'Leary; Peter Bacchetti; Richard A Kronmal Journal: AIDS Date: 2009-09-10 Impact factor: 4.177
Authors: Avni H Thakore; Chao-Yu Guo; Martin G Larson; Diane Corey; Thomas J Wang; Ramachandran S Vasan; Ralph B D'Agostino; Izabella Lipinska; John F Keaney; Emelia J Benjamin; Christopher J O'Donnell Journal: Am J Cardiol Date: 2007-04-18 Impact factor: 2.778
Authors: Ahmed Tawakol; Amorina Ishai; Danny Li; Richard A P Takx; Sophia Hur; Yannick Kaiser; Miguel Pampaloni; Adam Rupert; Denise Hsu; Irini Sereti; Rémi Fromentin; Nicolas Chomont; Peter Ganz; Steven G Deeks; Priscilla Y Hsue Journal: JAMA Cardiol Date: 2017-02-01 Impact factor: 14.676
Authors: N E Kelso-Chichetto; M Plankey; D S Sheps; A G Abraham; X Chen; S Shoptaw; R C Kaplan; W S Post; R L Cook Journal: Drug Alcohol Depend Date: 2017-10-28 Impact factor: 4.492
Authors: Mabel Toribio; Kathleen V Fitch; Laura Sanchez; Tricia H Burdo; Kenneth C Williams; Craig A Sponseller; Mary McCurdy Pate; Judith A Aberg; Markella V Zanni; Steven K Grinspoon Journal: AIDS Date: 2017-03-27 Impact factor: 4.177
Authors: Arcadio Agudelo-Hernandez; Yue Chen; Arlene Bullotta; William G Buchanan; Cynthia R Klamar-Blain; Luann Borowski; Sharon A Riddler; Charles R Rinaldo; Bernard J C Macatangay Journal: AIDS Date: 2017-09-24 Impact factor: 4.177
Authors: Sumbal A Janjua; Pedro V Staziaki; Balint Szilveszter; Richard A P Takx; Thomas Mayrhofer; Orla Hennessy; Hamed A Emami; Jakob Park; Alexander Ivanov; Travis R Hallett; Michael T Lu; Javier M Romero; Steven K Grinspoon; Udo Hoffmann; Markella V Zanni; Tomas G Neilan Journal: Circ Cardiovasc Imaging Date: 2017-10 Impact factor: 7.792
Authors: David B Hanna; Jee-Young Moon; Sabina A Haberlen; Audrey L French; Frank J Palella; Stephen J Gange; Mallory D Witt; Seble Kassaye; Jason M Lazar; Phyllis C Tien; Matthew J Feinstein; Lawrence A Kingsley; Wendy S Post; Robert C Kaplan; Howard N Hodis; Kathryn Anastos Journal: AIDS Date: 2018-10-23 Impact factor: 4.177